Flexilax

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flexilax

Quick Facts
Active Component Baclofen (Single Active Ingredient)
Form Oral Film-Coated Tablet
Pharmacological Class Centrally Acting Skeletal Muscle Relaxant
Primary Indication Spasticity due to Multiple Sclerosis, Spinal Cord Injury
Regulatory Status Prescription Only (Rx)

What Type of Medicine is Flexilax?

Flexilax is a brand-name, prescription-only medication whose active ingredient is Baclofen, a compound categorized as a gamma-aminobutyric acid (GABA) derivative. It belongs to the class of centrally acting skeletal muscle relaxants. Flexilax is clinically recognized for its targeted action primarily at the spinal cord level, making it a key therapy for chronic conditions that involve persistent muscle overactivity. Pharmacological studies confirm its specific interaction with GABAB receptors, providing a scientifically supported mechanism for reducing muscle rigidity and spasms. This scientific confirmation means the drug specifically targets the nerve signaling pathways responsible for muscle rigidity and spasms.

What Is Flexilax Made Of and How Is It Formulated?

Flexilax is a synthetic pharmaceutical containing Baclofen as its single primary active ingredient. It is manufactured as an oral film-coated tablet, a dosage form designed for easy ingestion and reliable systemic absorption. This specific tablet form, combined with its prescription-only status, differentiates it from over-the-counter muscle relief options, indicating its use for more severe, medically monitored conditions.

What is the General Therapeutic Purpose of Flexilax?

The general therapeutic purpose of Flexilax is to provide sustained relief from the rigidity, tension, and stiffness (spasticity) associated with chronic neurological conditions. Its primary uses include easing symptoms related to multiple sclerosis and spinal cord injuries. The medication aims to reduce the painful, involuntary muscle contractions that severely limit mobility. By relaxing overly tense muscles, Flexilax supports overall comfort and is clinically used to help improve a patient’s ability to perform daily activities. In summary, Flexilax helps restore mobility and comfort by calming the excessive nerve signals that cause spasticity.

Regulatory References

  1. Baclofen - LiverTox - NCBI Bookshelf - NIH
  2. Baclofen: MedlinePlus Drug Information

What side effects are possible with Flexilax?

Possible side effects and safety information

The safety profile of Flexilax, whose active component is Baclofen, is based on official government regulatory classifications of adverse reactions by frequency and organ system involvement. Adverse effects are primarily associated with its action on the central nervous system (CNS).

Frequency-Classified Adverse Reactions

The most frequently reported adverse reaction is somnolence (drowsiness), which is formally classified as Very Common in regulatory documents. Other adverse effects classified as Common include dizziness, fatigue, weakness, headache, insomnia, and confusion, as well as gastrointestinal effects such as nausea and constipation. These reactions are often reported to be more frequent at the start of treatment or following dose increases.

System-Organ Classes and Serious Reactions

Adverse reactions are grouped into official System-Organ Classes (SOCs), with the Nervous System Disorders, Gastrointestinal Disorders, and Psychiatric Disorders being prominently involved. A serious safety consideration explicitly documented in regulatory labeling is the risk of a Withdrawal Syndrome, which can occur if the medication is abruptly discontinued. This syndrome is a cluster of severe effects that may include increased spasticity, hallucinations, and seizures.

Population and Exposure Safety Notes

Official safety documents include specific considerations for certain patient groups. Older adults are noted to be more susceptible to adverse CNS effects like somnolence and confusion. Caution is also explicitly required for patients with renal impairment due to the risk of systemic accumulation and potential toxicity. The need for gradual discontinuation is a fundamental regulatory requirement to mitigate the risk of the severe Withdrawal Syndrome.

Overdose and Emergency Response

Overdose and When to Seek Help

Flexilax (also known as cyclobenzaprine) overdose may lead to serious, potentially fatal effects, primarily involving the central nervous and cardiovascular systems. Immediate emergency medical attention is required if an overdose is suspected.

Documented Overdose Symptoms

Common manifestations include profound drowsiness, tachycardia (rapid heart rate), agitation, confusion, and hallucinations. More severe, life-threatening symptoms are rare but can include cardiac arrest, severe hypotension (low blood pressure), cardiac dysrhythmias, and seizures.

Risk Factors and Urgent Action

Overdose risk is elevated in certain populations, including elderly individuals and patients with hepatic impairment, as their bodies may clear the drug more slowly. Critically, concomitant use with MAO inhibitors is strictly contraindicated due to the potential for a fatal hyperpyretic crisis. Use with other serotonergic drugs can also precipitate a life-threatening condition called Serotonin Syndrome (symptoms include severe agitation, fever, and muscle rigidity), which requires immediate drug discontinuation and supportive treatment.

If overdose is suspected, call a Poison Help line or seek emergency medical help immediately. Treatment requires hospital monitoring of vital signs and an ECG due to the risk of heart rhythm abnormalities.

Therapeutic Uses of Flexilax

Quick Facts

  • Primary Use: Management of muscle spasms.
  • Target Conditions: Acute, painful musculoskeletal conditions.
  • Goal of Therapy: Supports relief of muscle spasm and associated discomfort.

Flexilax is approved as an adjunct to other supportive therapies, such as rest and physical therapy, for the management of muscle spasms. Its therapeutic domain focuses on acute, painful conditions involving skeletal muscles.

The medication is used to support the relief of muscle spasm and the associated signs and symptoms that may include localized pain, tenderness, and limitation of motion. By supporting the reduction of muscle hyperactivity, Flexilax may help improve the patient's functional status, which assists in daily activities.

The use of this medication is typically reserved for short-term management, as defined by safety and effectiveness guidance, due to the generally short-term duration of acute muscle spasm conditions. Flexilax is not intended for the treatment of spasticity caused by neurological diseases.

Eligibility and Restrictions for Use

The eligibility profile for Flexilax is determined by official regulatory classifications regarding patient age, pre-existing conditions, and physiological status. The absolute prohibition for the medicine is narrowly defined, while conditional use is described for several patient populations.

Population Status Regulatory Rule
Contraindicated Use is absolutely prohibited in patients with known hypersensitivity to baclofen or any component in the formulation.
Use Not Established Safety and effectiveness for the oral formulation have not been established in pediatric patients below 12 years of age.
Caution Required Use in older adults requires caution due to potential increased sensitivity. Caution is also mandatory for patients with impaired renal function due to slower drug clearance.
Comorbidity Warning Caution is required for patients with a history of epilepsy, cerebrovascular disease (e.g., stroke), or pre-existing psychotic disorders, as these conditions may be worsened or poorly tolerated.
Reproductive Status Use during pregnancy is permitted only if the benefit clearly justifies the potential risk to the fetus. The drug is excreted into breast milk; use must be determined by weighing the potential risk against the benefit.

Flexilax is not indicated for skeletal muscle spasm resulting from rheumatic disorders, defining a specific population for whom its use is excluded under standard labeled conditions. The overall profile mandates strict adherence to these eligibility restrictions defined in official government documents.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Flexilax is structured around documented pharmacodynamic and pharmacokinetic interaction concerns as defined in authoritative governmental documents.

Pharmacodynamic and Additive CNS Effects

Co-administration with alcohol and other CNS Depressants (including opioids and benzodiazepines) is documented as a pharmacodynamic interaction. This combination leads to additive central nervous system effects, potentially increasing sedation, drowsiness, and the risk of respiratory depression.

  • Antihypertensive Agents may increase the risk of hypotension when combined with Flexilax.
  • Combinations with Tricyclic Antidepressants may potentiate the substance's effect, leading to pronounced muscular hypotonia.
  • MAO Inhibitors may also result in increased CNS depressant effects when co-administered.

Pharmacokinetic and Clearance-Related Concerns

The main pharmacokinetic restriction involves the drug's primary elimination pathway. Baclofen is excreted largely unchanged by the kidneys. Consequently, the concurrent use of medicinal products that significantly impact renal function may reduce Baclofen's clearance, potentially resulting in elevated plasma levels and the risk of drug toxicity.

  • Population Note: This risk of reduced clearance and accumulation is significantly heightened in patients with impaired renal function.
  • Food Interaction: Administration of the oral formulation with a high-fat meal may decrease the systemic exposure (AUC and Cmax) of the drug.

No mandatory timing separation rules are established in the official labeling for Flexilax.

Mechanism of Action

Flexilax functions as an agonist at the GABAB receptors, primarily accumulating and exerting its effect at the spinal level of the central nervous system. This molecular interaction with the G-protein coupled GABAB receptor initiates an intracellular cascade that modulates presynaptic activity. G-protein activation leads to the opening of potassium channels and the inhibition of voltage-gated calcium channels, resulting in hyperpolarization of the neuronal membrane and a reduction in neuronal excitability. The presynaptic consequence of this action is the inhibition of excitatory neurotransmitter release, specifically glutamate and aspartate, from primary afferent terminals. This reduction in excitatory signaling at the spinal cord effectively depresses the activity of both monosynaptic and polysynaptic reflex arcs. The downstream cascade limits the aberrant firing of alpha-motor neurons. The system-level physiological consequence is a generalized modulation of increased skeletal muscle tone due to reduced reflex-mediated muscle hyperactivity.

Dosage and Administration Information

How to Use Flexilax (Baclofen) — Administration Guidelines

Flexilax (Baclofen) is administered according to standardized protocols to ensure proper use and minimize the risk of adverse events. The instructions below describe the procedure for oral administration.


Oral Dosing and Frequency

Treatment initiation requires a titration schedule where the dose is increased slowly and gradually. Abrupt discontinuation of the drug is avoided due to the risk of severe withdrawal symptoms.

Category Instruction
Route of Administration Oral (tablets, solution, or granules). Intrathecal administration is reserved for severe cases.
Adult Starting Dose Typically 5 mg taken three times a day (TID).
Titration Schedule Dose should be increased every three days, usually by 5 mg per dose, until the required effect is achieved.
Maximum Daily Dose Generally should not exceed 80 mg in divided doses for adults.

Administration Conditions and Procedures

Category Instruction
Timing with Meals Oral tablets should be taken with or immediately after food or a small amount of liquid to limit gastrointestinal irritation.
Tablet Integrity Tablets should be swallowed whole and must not be chewed, crushed, or broken.
Discontinuation The dose must be slowly reduced over a period of 1 to 2 weeks (or more) before stopping therapy.
Special Populations Elderly patients and those with renal impairment should begin at a reduced starting dose (e.g., 5 mg daily) and be monitored closely during titration.

Official Procedural Summary

Therapy starts with a low dose and follows a gradual increase over several weeks. If there is no beneficial response after 6 to 8 weeks at the maximum recommended dosage, the drug is slowly withdrawn rather than stopped suddenly.

Recent Clinical Evidence

Flexilax: Recent Clinical Evidence

Clinical data on Flexilax (generic name baclofen) consistently support its efficacy as a centrally acting skeletal muscle relaxant and antispasticity agent. It is primarily indicated for the management of spasticity resulting from conditions such as Multiple Sclerosis (MS), spinal cord injuries, and other spinal cord diseases, which includes relief of associated flexor spasms, pain, and muscular rigidity. The mechanism of action involves stimulating GABA B receptors at the spinal level, inhibiting the release of excitatory neurotransmitters like glutamate and aspartate, which helps to reduce nerve signaling responsible for muscle overactivity.


Efficacy and Indications

Randomized controlled trials (RCTs) confirm the drug's role in improving muscle hypertonicity and involuntary jerks, which are hallmarks of spasticity. Specifically, Flexilax has been shown to effectively relieve muscle stiffness or spasm, thereby enhancing muscle movement and function in affected individuals. Its anti-nociceptive (pain-relieving) properties are also observed, contributing to an overall improvement in a patient’s quality of life. The choice between Flexilax and other skeletal muscle relaxants is often guided by the specific type of muscle condition (spasticity vs. local muscle spasm), the drug's adverse effect profile, tolerability, and individual patient needs.


Safety Profile and Considerations

The most common adverse reactions reported in clinical studies include drowsiness, dizziness, weakness, and fatigue. Caution is advised, and dosage adjustment may be required in patients with pre-existing conditions affecting the kidneys or liver. Clinical evidence strongly suggests that abrupt discontinuation of Flexilax, particularly after prolonged use, may lead to withdrawal symptoms, including seizures, necessitating a gradual tapering of the dosage under medical supervision. The medication is generally recommended for use under appropriate supervision, especially in patients with a history of epilepsy, where a lowering of the convulsion threshold may occur.

Frequently Asked Questions (FAQ)

Common questions about Flexilax (FAQ)


Q: Is Flexilax considered a long-term treatment or just for short-term use?

A: Flexilax is often used in the management of chronic muscle spasticity and, according to official information, is generally considered suitable for long-term use. However, treatment is always started with a gradual dose increase, and the medication must be slowly reduced and should not be stopped suddenly, even after prolonged use.


Q: Can Flexilax be taken at the same time as my daily vitamins?

A: Regulatory documents do not specifically list common daily vitamins as a drug interaction concern for Flexilax. Nonetheless, caution is advised with herbal remedies and certain supplements. Regulatory guidance suggests patients inform their prescribing health professional about all vitamins and supplements being taken.


Q: How quickly does Flexilax typically start working?

A: Initial positive effects of Flexilax may begin to be noticeable after a few days of taking the medication regularly. Official product information indicates that it may take up to ten days to experience the maximum effect of the initial treatment phase.


Q: What happens if I miss a dose of Flexilax?

A: Official guidance indicates that if a dose is missed, it should be taken as soon as it is remembered. However, if the time for the next dose is rapidly approaching (such as within a few hours for a three-times-a-day schedule), the missed dose should generally be skipped to prevent taking doses too close together. Regulatory information cautions against taking a double dose to compensate for a missed one.


Q: Can I take Flexilax if I have certain stomach or intestinal issues?

A: Caution is advised in official drug labels for patients who have a history of peptic ulcer or certain other pre-existing gastrointestinal disorders. Official labels state that Flexilax can affect conditions like peptic ulcer disease.


Q: Are the side effects of Flexilax the same for everyone?

A: Side effects are not necessarily the same for every person using Flexilax, and their severity can vary. Regulatory documents note that special caution is advised for certain groups, such as older adults and patients with kidney issues, as they may be more susceptible to experiencing central nervous system side effects.


Q: How long do the effects of Flexilax usually last after a single use?

A: The plasma elimination half-life—the time it takes for half of the medication to be cleared from the bloodstream—is approximately 3 to 4 hours. This time frame informs the typical dosing frequency of the medication, which is generally three times a day.


Q: Can Flexilax be taken with pain relievers like ibuprofen?

A: Official drug labels indicate that caution should be exercised with the co-administration of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen. This combination may potentially increase the risk of side effects. Patients are generally advised to discuss all combined medication use with a healthcare provider.


Q: What is the main difference between Flexilax and common over-the-counter options?

A: Flexilax contains the active ingredient Baclofen, which is classified as a prescription-only medication. It is primarily indicated for treating spasticity resulting from chronic conditions like multiple sclerosis, distinguishing its use from over-the-counter options typically aimed at general muscle soreness from rheumatic conditions.


Q: What does 'contraindication' mean in the context of Flexilax?

A: In regulatory documents, a contraindication is a factor or specific condition that makes the use of a medicine absolutely forbidden. For Flexilax, the absolute contraindication is a known hypersensitivity—a severe allergic reaction—to the active ingredient (Baclofen) or any part of the formulation.


Q: Are there official limits on how long Flexilax can be used?

A: There is no stated maximum duration of use; the drug is approved for the management of chronic conditions. However, regulatory guidelines state that if a patient does not show a beneficial response after a period of time, the drug should be slowly withdrawn rather than continued.


Q: Does Flexilax interact with birth control pills?

A: Official product information suggests that Flexilax does not affect the contraceptive effectiveness of combined or emergency birth control pills. However, if the medication causes severe vomiting or diarrhea, the effectiveness of the contraceptive pill could be indirectly reduced.


Q: Can I take Flexilax if I have allergies to other medications?

A: Flexilax is contraindicated if there is a known hypersensitivity to Baclofen or any component of its formulation. While general drug allergies are not specific contraindications, official guidelines recommend disclosing all drug sensitivities to a health professional.


Q: Is Flexilax manufactured in different strengths?

A: Yes, the active ingredient Baclofen is available in various strengths and dosage forms. Regulatory information indicates that oral tablets are typically available in 10 mg and 20 mg strengths to accommodate the individual dose titration schedule.


Q: What are the serious, but rare, side effects of Flexilax?

A: Official safety warnings explicitly document the risk of a severe Withdrawal Syndrome if the medication is stopped suddenly. This serious adverse effect may include symptoms such as seizures, hallucinations, and high fever, necessitating a gradual dosage reduction under medical supervision.


Q: Does Flexilax interact with supplements like St. John's Wort?

A: There is generally not enough regulatory information to definitively state that all herbal remedies or supplements are safe to take alongside Flexilax, as they are not subjected to the same formal interaction testing as prescription drugs. It is recommended that patients discuss the use of herbal remedies or supplements with a healthcare provider.


Q: Is Flexilax a controlled substance?

A: Official classification in the United States indicates that Baclofen is not listed as a federally controlled substance. However, regulatory documents caution that the drug has been associated with reports of misuse and abuse due to its central nervous system effects. The drug's regulatory profile notes that special monitoring may be required for certain patient groups.


Q: What is the definition of 'maximum benefit' when talking about Flexilax?

A: In regulatory terms, the maximum benefit is achieved when the lowest possible dose that results in the optimal clinical response (the best relief of spasticity symptoms) is determined. This therapeutic goal may take several weeks to reach through the required gradual dose increase process.


Q: Is it possible to become dependent on Flexilax?

A: Regulatory documents explicitly report that cases of misuse, abuse, and physical dependence have been associated with the active ingredient in Flexilax. Due to the risk of dependence with long-term use, official guidelines mandate that the medication must be stopped via a gradual dose reduction procedure directed by a health professional.


Q: Does Flexilax have a known withdrawal period when stopping use?

A: Yes, official warnings document the need to stop the medication by slowly reducing the dose over a period of 1 to 2 weeks or more. This gradual process is mandatory to mitigate the risk of a severe Withdrawal Syndrome, which includes symptoms like seizures and worsening spasticity.


Q: Are there different brand names for the same medicine as Flexilax?

A: Yes, the active ingredient Baclofen is available under various commercial names worldwide, in addition to generic formulations. Some examples of other brand names include Lioresal, Gablofen, and Ozobax.


Q: What official body approved Flexilax for use?

A: The active ingredient in Flexilax, Baclofen, has received approval for use from major drug regulatory bodies globally. These include authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), which regulate its use and labeling.


Q: How long does it take for Flexilax to be completely out of the system?

A: The active component is eliminated largely unchanged, primarily by the kidneys. While the elimination half-life averages 3 to 4 hours, regulatory data indicates that approximately 75% of the dose is typically excreted within 72 hours of administration.


Q: Is it normal to feel a change in appetite while using Flexilax?

A: Official drug information documents list changes in appetite as a possible side effect. Specifically, loss of appetite is noted in some adverse reaction classifications associated with Baclofen use.


Q: Can taking Flexilax cause skin sensitivity or rash?

A: Yes, the official adverse reaction lists associated with Flexilax include the potential for allergic reactions. These reactions may sometimes present as dermatological symptoms such as a skin rash, itching, or hives.

How should Flexilax be stored and disposed of?

How to Store and Dispose of Flexilax?

This medicine must be stored according to strict regulatory requirements to maintain its stability and potency.

Storage and Handling Conditions

Condition Requirement
Maximum Temperature Store below 30 C (in a cool place).
Environmental Protection Protect strictly from light and moisture.
Container Integrity Store in a dry place, preferably in the original packaging.
In-Use Stability For certain liquid preparations, discard any unused medicine two months after the first opening.

Safety and Disposal

It is an explicit regulatory requirement to keep Flexilax strictly out of the reach of children to prevent accidental ingestion. Official governmental documentation does not typically provide universally applicable disposal instructions, which must instead align with local guidelines for discarding unused medicines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Flexilax found in:

A-Z Index: